🔬Spotlight :

A Breakthrough in Tumor Immunity Detection

AND-gated nanosensors improve cancer therapy detection by increasing specificity and minimizing off-target signals. These nanosensors are designed to release a reporter only when activated by a specific pair of proteases, such as granzyme B (GzmB) secreted by CD8+ T cells and matrix metalloproteinases (MMPs) overexpressed by cancer cells. This design enables the sensors to identify the unique condition of cytotoxic T cell killing of tumor cells, which is key for effective cancer therapy.

Here's a breakdown of the key improvements:

• Increased Specificity: AND-gated nanosensors require the presence of two specific proteases to be activated. This significantly reduces the chance of false positives compared to sensors that respond to a single protease. For example, in a mouse model of acute viral infection, linear GzmB nanosensors showed high fluorescence in the lungs, while AND-gated nanosensors did not. This demonstrates that the AND-gate logic minimizes signals from tissues without co-localized protease expression.

• Discrimination of Anti-Tumor Responses: The AND-gated nanosensors can distinguish between conditions where T cells are killing cancer cells and situations where only tumor cells or T cells are present. In co-culture experiments, the sensors showed significant activation only when T cells were mixed with tumor cells pulsed with a cognate antigen.

• Monitoring Immunotherapy Response: In preclinical mouse models, AND-gated nanosensors successfully differentiated tumors that are responsive to immune checkpoint blockade therapy (ICBT) from those that are resistant. The nanosensors showed higher fluorescence in tumors of mice treated with ICBT compared to those treated with isotype control antibodies.

• Detection in Urine: AND-gated nanosensors can be designed to release reporters that are small enough to be filtered by the kidneys and concentrated in urine. This allows for non-invasive monitoring of therapy response by quantifying urinary reporters. The urinary reporter levels were significantly elevated in mice treated with ICBT compared to mice with isotype antibodies or ICBT-treated mice bearing B2m–/– tumors.

• Multivalent Presentation: Conjugating cyclic peptides to iron oxide nanoparticles (IONPs) increases the catalytic efficiency of the nanosensors by increasing local substrate concentrations. This allows enzymes to ‘hop’ between substrates on the nanoparticle, increasing cleavage rates. The catalytic efficiency of GzmB for cyclic peptides was significantly increased when the peptides were conjugated to IONPs.

• Improved Selectivity: AND-gated nanosensors had significantly higher activation in ICBT-responding tumors than in the majority of non-tumor organs compared to linear GzmB nanosensors, leading to higher tumor selectivity. This indicates that the AND-gated design improves on-tumor specificity compared to sensors that respond to a single protease.

The study also demonstrated the modularity of the AND-gated nanosensor design by substituting substrates with sequences responsive to other proteases, including thrombin, legumain, and fibroblast activation protein. This suggests the platform could be adapted to detect a variety of cell types involved in cancer progression or anti-tumor responses.

In summary, AND-gated nanosensors, through their logical gating and multivalent presentation, provide a more precise and specific method for detecting anti-tumor immune responses than single-target sensors, which may improve the monitoring of cancer therapy effectiveness.

🎙️Podcast Overview (Click Here)

💡Pro Tip For Aspiring LabRatz!

If It’s Not in Your Lab Notebook, It Didn’t Happen!